Multiomics Market Size & Outlook, 2025-2033

Multiomics Market Size

The global multiomics market size was valued at USD 2.56 billion in 2024 and is projected to grow from USD 2.95 billion in 2025 to reach USD 9.16 billion by 2033, growing at a CAGR of 15.22% during the forecast period (2025–2033).

A major driver of the global multiomics market is the rising demand for precision diagnostics and personalized medicine. Multiomics enables a comprehensive understanding of biological systems by integrating genomics, proteomics, transcriptomics, and metabolomics, allowing researchers and clinicians to detect diseases earlier and tailor treatments more accurately. This is particularly impactful in complex diseases like cancer, where individual variability plays a critical role in treatment response.

Additionally, increased funding from governments, research organizations, and private investors is accelerating technological advancements and supporting multiomics-based studies. Projects such as the NIH’s All of Us Research Program and the UK Biobank are generating large-scale, multi-layered datasets that enhance research and clinical applications. Furthermore, the growing adoption of this solution in epidemiology and public health studies is further boosting market growth as healthcare shifts toward more personalized, data-driven solutions.

Current Market Trends

Integration of Ai and Big Data Analytics

The integration of artificial intelligence (AI) and big data analytics is revolutionizing the global multiomics market by enabling efficient processing and interpretation of massive, complex datasets. Multiomics approaches, encompassing genomics, transcriptomics, proteomics, and metabolomics, generate vast volumes of data, often requiring advanced computational tools for actionable insights. AI algorithms can identify hidden patterns and correlations within these datasets, improving disease prediction, drug response profiling, and biomarker discovery.

• For instance, in a February 2025 study, the Mayo Clinic introduced OmicsFootPrint, an AI-driven tool that converts complex multiomics data into intuitive circular heatmaps. Demonstrating ~87% accuracy in differentiating breast cancer subtypes, it exemplifies how AI facilitates interpretability and clinical application of this solution.

As healthcare moves toward precision medicine, the synergy between AI and multiomics is expected to become a cornerstone for diagnostics and therapeutic innovations.

To get more insights about this report Download Free Sample Report

Multiomics Market Driving Factors

Surge in Chronic Diseases and Complex Disorders

The global rise in chronic diseases and complex disorders is significantly propelling the demand for multiomics technologies. As conditions like cancer, cardiovascular diseases, diabetes, and autoimmune disorders become more prevalent, there is a growing need for advanced molecular-level diagnostics and personalized treatments. Multiomics integrates genomics, proteomics, transcriptomics, and metabolomics, enabling comprehensive disease profiling and enhancing precision medicine.

• According to the WHO, chronic diseases now account for approximately 74% of all global deaths. Cardiovascular diseases were the leading cause of death from chronic disease, responsible for over 19 million fatalities. They were followed by cancers, which caused around 10 million deaths, chronic respiratory diseases, with 4 million deaths, and diabetes, which accounted for more than 2 million deaths.

Such alarming statistics underscore the urgency for innovative tools like multiomics to understand disease mechanisms and design targeted therapies.

Market Restraining Factors

High Cost and Technical Complexity

One of the major restraints in the global market is the high cost and technical complexity associated with its implementation. Multiomics studies require advanced equipment such as next-generation sequencing systems, mass spectrometers, and high-performance computing infrastructure for data analysis.

Additionally, integrating and interpreting complex datasets from genomics, transcriptomics, proteomics, and metabolomics demands specialized bioinformatics expertise. This significantly increases the operational cost and creates a barrier for small laboratories and research institutions with limited budgets. Moreover, the lack of standardized protocols for multiomics data processing further adds to the complexity, delaying widespread adoption, especially in developing countries with constrained healthcare and research funding.

Market Opportunities

Expanding Role in Drug Development

The growing integration of multiomics in drug development is opening significant opportunities for market expansion. By combining genomics, transcriptomics, proteomics, and metabolomics, this solution provides a comprehensive view of disease biology, enabling pharmaceutical companies to identify novel drug targets, predict therapeutic responses, and reduce trial-and-error in clinical trials.

• For instance, in February 2025, Illumina unveiled new technologies, including 5-base sequencing, spatial transcriptomics, single-cell Perturb-seq, and the Illumina Connected Multiomics software suite, set for launch between 2025 and 2026. These innovations aim to streamline simultaneous genetic and epigenetic profiling, empowering drug discovery and translational research.

Such advancements not only accelerate the drug development pipeline but also reduce associated costs and risks. As regulatory agencies increasingly support biomarker-driven approvals, multiomics will continue to play a pivotal role in shaping the future of precision therapeutics.

Regional Insights

North America leads the multiomics market due to advanced healthcare infrastructure, substantial R&D investments, and early adoption of next-generation sequencing and AI-driven analytics. Strong academic-industry collaborations and increasing focus on personalized medicine are key drivers. The presence of well-established biotech firms and growing integration of multiomics in clinical workflows, especially in oncology and rare disease research, supports regional growth. Additionally, supportive regulatory frameworks and funding from public and private sectors are accelerating clinical applications of multiomics across hospitals, research centers, and diagnostic laboratories.

U.s. Multiomics Market Trends

• The United States market is thriving due to strong R&D investments and a robust biotech ecosystem. Institutions like NIH and companies such as Thermo Fisher Scientific and Illumina drive innovation in genomics, proteomics, and metabolomics. For example, the All of Us Research Program integrates multiomics to advance precision medicine; additionally, collaborations between pharma and academia foster biomarker discovery and cancer diagnostics using integrated omics platforms.
• Canada’s multiomics market is growing steadily, driven by government-backed genomics initiatives and collaborative research hubs. Genome Canada funds several multiomics projects focused on population health and rare disease research. For example, the Canadian Multi-Omics Platform (CanMOP) supports data integration for cancer and neurodegenerative disease studies. With strong academic-industry partnerships, Canada is establishing itself as a key contributor to global multiomics innovation.

Asia Pacific Multiomics Market Trends

The Asia Pacific region is witnessing rapid growth in the global market due to expanding biomedical research capabilities, rising healthcare expenditure, and increasing awareness of precision medicine. Governments and private sectors are heavily investing in genomics and biotechnology, accelerating the adoption of multiomics platforms. The growing prevalence of chronic diseases and large-scale population health initiatives is fueling demand for integrative omics solutions. Academic institutions are partnering with tech and pharma companies to enhance omics-based diagnostics and therapeutic development, fostering a strong regional foundation for future multiomics innovations.

• China’s multiomics market is expanding due to strong government support for precision medicine and biotech. Initiatives like "China Precision Medicine Initiative" aim to integrate genomics and clinical data for disease research. Companies like BGI Genomics and WuXi NextCODE are investing heavily in omics platforms. Increasing cancer prevalence and collaborations with international pharma firms further drive growth, especially in oncology-focused multiomics research.
• India’s multiomics industry is gaining traction with growing investment in genomic research and digital health. The government-backed Genome India Project aims to sequence 10,000 Indian genomes, supporting disease biology studies. Biotech firms like MedGenome and Mapmygenome are expanding multiomics services in diagnostics and personalized medicine. With a high burden of diabetes and cardiovascular diseases, India is using multiomics for biomarker discovery and clinical insights.

Europe Multiomics Market Trends

Europe’s market is driven by robust government support for precision medicine initiatives and increasing clinical adoption of omics technologies. The region exhibits strong regulatory and ethical governance for genomics and data-driven healthcare. Funding from regional research programs and public health agencies is fostering translational research in multiomics. Moreover, the focus on developing personalized therapies and biomarker-driven drug development, especially in neurodegenerative and cardiovascular diseases, is spurring market growth. Europe's growing digital health ecosystem and emphasis on data interoperability further enhance the integration of multiomics into healthcare.

• Germany’s market for multiomics is experiencing robust growth due to its strong biotechnology ecosystem and government-backed initiatives like the GenomDE project, which aims to integrate genomic data into healthcare. German research institutes like the Max Planck Society and companies like BioNTech are leveraging multiomics in personalized medicine and oncology. High investment in omics-based clinical diagnostics and collaborations with EU partners further bolsters the country’s market presence.
• The UK multiomics industry is expanding significantly, driven by large-scale projects like Genomics England’s 100,000 Genomes Project, which incorporates multiomics data for rare disease and cancer research. The NHS’s support for integrating multiomics in routine diagnostics and collaborations with academic institutions such as the University of Oxford and biotech firms like Oxford Nanopore enhances market penetration. Strong regulatory frameworks and innovation funding make the UK a key regional player.

Product & Service Insights

The products segment dominates the global market due to the surging demand for advanced instruments, consumables, and analytical software essential for omics research. Continuous technological innovations in sequencing and mass spectrometry platforms drive adoption among researchers and diagnostic labs. The growing need for high-throughput systems and data analysis tools further supports the segment’s leadership, especially as multiomics becomes integral to precision medicine and translational research.

Type Insights

Bulk multiomics holds the largest market share owing to its widespread application in population-level studies and disease mechanism research. It enables comprehensive profiling of DNA, RNA, proteins, and metabolites across large sample sets, offering cost-effective scalability. Bulk analysis is particularly favored in pharmaceutical research and biomarker discovery, where individual cell resolution is not required. Its established methodologies and lower cost compared to single-cell approaches contribute to its dominance.

Platform Insights

Genomics leads the platform segment in the market due to its foundational role in molecular biology and systems medicine. It serves as the starting point for integrating other omics layers like transcriptomics and proteomics. Advancements in next-generation sequencing (NGS) technologies and decreasing sequencing costs have boosted genomic data generation. Its critical role in understanding genetic predispositions, mutations, and therapeutic targets positions genomics as the most utilized platform in multiomics studies.

Application Insights

The drug discovery and development segment is a major application area in the global market, driven by the need to streamline target identification, optimize candidate selection, and predict drug response. Multiomics provides a holistic view of disease biology, enabling more accurate biomarker validation and mechanistic insights. Pharmaceutical companies increasingly adopt multiomics to reduce R&D costs and improve clinical success rates, enhancing therapeutic innovation and personalized treatment strategies.

End-User Insights

Academic and research institutes dominate the end-user segment due to their central role in basic and translational multiomics research. These institutions drive innovation through government and private funding, focusing on unraveling disease mechanisms and advancing personalized medicine. The presence of skilled researchers, high-end facilities, and collaborative projects further boosts the segment’s growth. Their contribution to technology validation and data generation solidifies their leadership in the global market.

Company Market Share

Companies in the multiomics market are focusing on expanding their portfolios by integrating advanced technologies such as AI, cloud computing, and high-throughput sequencing platforms. They are investing heavily in R&D, forming strategic partnerships with academic institutions and biotech firms, and acquiring startups to enhance capabilities. Additionally, efforts are being made to offer end-to-end solutions and cloud-based analytics platforms to streamline data interpretation and improve adoption across clinical and research settings.

Bruker Corporation: Bruker Corporation is a prominent player in the global market, specializing in high-performance scientific instruments and analytical solutions. The company offers advanced mass spectrometry, NMR spectroscopy, and proteomics technologies crucial for genomics, metabolomics, and proteogenomics research. Headquartered in Massachusetts, USA, Bruker supports pharmaceutical, clinical, and academic research worldwide. Its innovative platforms, such as the timsTOF series, enable high-resolution biomolecular analysis, enhancing capabilities in biomarker discovery, disease profiling, and personalized medicine. Bruker’s strategic acquisitions and R&D investments reinforce its multiomics portfolio.

• In April 2025, Bruker Corporation unveiled CosMx WTX assay that enables simultaneous spatial profiling of ~19k transcripts and ~76 proteins on a single slide. Additionally, the enhanced nCounter platform integrates high‑plex bulk RNA and protein panels. These innovations offer comprehensive, spatially resolved multiomics analysis for both research and clinical applications.

List of key players in Multiomics Market

1. Illumina, Inc.
2. Thermo Fisher Scientific Inc.
3. Agilent Technologies, Inc.
4. QIAGEN N.V.
5. Bio-Rad Laboratories, Inc.
6. BGI Group
7. Bruker Corporation
8. Waters Corporation
9. PerkinElmer, Inc.
10. Danaher Corporation

To get more findings about this report Download Market Share

Recent Developments

• June 2025- DeepMind released AlphaGenome, an AI model that analyzes up to 1 million DNA base pairs to predict gene regulation effects, covering expression, splicing, chromatin activity, and transcription factor binding. Available via API for non-commercial research, it outperforms previous tools in most genomic prediction tasks.
• April 2025- Signios Bio launched an AI-powered multiomics platform integrating genomics, proteomics, transcriptomics, metabolomics, and spatial biology. The platform enables advanced biomarker discovery and accelerates drug development by offering comprehensive, automated data analysis. It targets collaborations with pharma, biotech, and academia to drive innovations in precision medicine and translational research.
• April 2025- Metabolon Inc. released an integrated Microbiome Research Solution that combines metagenomics, a targeted metabolite panel, and AI-enabled multiomics bioinformatics. The kit enables comprehensive microbiome function analysis, linking microbial composition to metabolic outputs.